1. Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats.
- Author
-
Nettore IC, Rocca C, Mancino G, Albano L, Amelio D, Grande F, Puoci F, Pasqua T, Desiderio S, Mazza R, Terracciano D, Colao A, Bèguinot F, Russo GL, Dentice M, Macchia PE, Sinicropi MS, Angelone T, and Ungaro P
- Subjects
- 3T3-L1 Cells, Adipocytes drug effects, Adipocytes pathology, Adipogenesis physiology, Animals, Anti-Obesity Agents pharmacology, Biological Availability, CCAAT-Enhancer-Binding Proteins genetics, CCAAT-Enhancer-Binding Proteins metabolism, Cell Survival drug effects, Chromatin metabolism, Diet, High-Fat adverse effects, Epigenesis, Genetic drug effects, Histones metabolism, Lipid Metabolism drug effects, Male, Mice, Obesity etiology, Obesity metabolism, PPAR gamma genetics, Quercetin pharmacokinetics, Rats, Wistar, Adipogenesis drug effects, Benzopyrans pharmacology, Chromatin drug effects, Obesity prevention & control, Quercetin pharmacology
- Abstract
Recently the attention of the scientific community has focused on the ability of polyphenols to counteract adverse epigenetic regulation involved in the development of complex conditions such as obesity. The aim of this study was to investigate the epigenetic mechanisms underlying the anti-adiposity effect of Quercetin (3,3',4',5,7-pentahydroxyflavone) and of one of its derivatives, Q2 in which the OH groups have been replaced by acetyl groups. In 3 T3-L1 preadipocytes, Quercetin and Q2 treatment induce chromatin remodeling and histone modifications at the 5' regulatory region of the two main adipogenic genes, c/EBPα and PPARγ. Chromatin immunoprecipitation assays revealed a concomitant increase of histone H3 di-methylation at Lys9, a typical mark of repressed gene promoters, and a decrease of histone H3 di-methylation at Lys 4, a mark of active transcription. At the same time, both compounds inhibited histone demethylase LSD1 recruitment to the 5' region of c/EBPα and PPARγ genes, a necessary step for adipogenesis. The final effect is a significant reduction in c/EBPα and PPARγ gene expression and attenuated adipogenesis. Q2 supplementation in rats reduced the gain in body weight and in white adipose tissue, as well as the increase in adipocyte size determined by high fat diet. Moreover, Q2 improved dyslipidemia, glucose tolerance and decreased the hepatic lipid accumulation by activating the expression of beta-oxidation related genes. Our data suggest that Q2, as well as Quercetin, has the potential to revert the unfavorable epigenomic profiles associated with obesity onset. This opens the possibility to use these compounds in targeted prevention strategies against obesity., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF